譬ｪ蠑丈ｼ夂､ｾ繝輔ぃ繝ｳ繝壹ャ繝�

FunPep Company Limited engages in the research and development of pharmaceuticals drugs, functional cosmetics, and medical devices in Japan and internationally. The company develops SR-0379, a functional peptide which is in Phase III clinical trial for the treatment of skin ulcer; FPP003, an antibody-inducing peptide which is in Phase II clinical trial for the treatment of psoriasis and ankylosing spondylitis; FPP004X, an antibody-inducing peptide which is in Phase I clinical trial for the treatment of pollinosis; and FPP005, an antibody-inducing peptide which is in pre-clinical trial stage for the treatment of psoriasis. It is also involved in the development of Curepeptin, an antimicrobial peptide that disrupts bacterial cell membranes. The company was incorporated in 2013 and is headquartered in Ibaraki, Japan.